310 related articles for article (PubMed ID: 19729086)
21. Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components.
Abdel-Aal AB; Zaman M; Fujita Y; Batzloff MR; Good MF; Toth I
J Med Chem; 2010 Nov; 53(22):8041-6. PubMed ID: 21028828
[TBL] [Abstract][Full Text] [Related]
22. FbaA- and M protein-based multi-epitope vaccine elicits strong protective immune responses against group A streptococcus in mouse model.
Ma C; Liu Z; Li W; Qian X; Zhang S; Gao X; Jiang S; Wei L
Microbes Infect; 2014 May; 16(5):409-18. PubMed ID: 24704476
[TBL] [Abstract][Full Text] [Related]
23. Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.
Gupta VK; Sekhar S; Dhanda V; Toor D; Kumar R; Chakraborti A
J Microbiol Immunol Infect; 2016 Jun; 49(3):352-8. PubMed ID: 25087198
[TBL] [Abstract][Full Text] [Related]
24. Prospects for a group A streptococcal vaccine.
McMillan DJ; Chhatwal GS
Curr Opin Mol Ther; 2005 Feb; 7(1):11-6. PubMed ID: 15732524
[TBL] [Abstract][Full Text] [Related]
25. Immune response to superoxide dismutase in group A streptococcal infection.
McMillan DJ; Davies MR; Good MF; Sriprakash KS
FEMS Immunol Med Microbiol; 2004 Apr; 40(3):249-56. PubMed ID: 15039102
[TBL] [Abstract][Full Text] [Related]
26. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage.
Horváth A; Olive C; Karpati L; Sun HK; Good M; Toth I
J Med Chem; 2004 Jul; 47(16):4100-4. PubMed ID: 15267249
[TBL] [Abstract][Full Text] [Related]
27. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
Pandey M; Mortensen R; Calcutt A; Powell J; Batzloff MR; Dietrich J; Good MF
J Immunol; 2016 Apr; 196(8):3364-74. PubMed ID: 26969753
[TBL] [Abstract][Full Text] [Related]
28. Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology.
Hayman WA; Toth I; Flinn N; Scanlon M; Good MF
Immunol Cell Biol; 2002 Apr; 80(2):178-87. PubMed ID: 11940119
[TBL] [Abstract][Full Text] [Related]
29. Immunity to group a streptococcal M proteins: forging a single-edged sword.
Madoff LC
Clin Infect Dis; 2005 Oct; 41(8):1123-4. PubMed ID: 16163630
[No Abstract] [Full Text] [Related]
30. Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.
Chuan YP; Wibowo N; Connors NK; Wu Y; Hughes FK; Batzloff MR; Lua LH; Middelberg AP
Biotechnol Bioeng; 2014 Jun; 111(6):1062-70. PubMed ID: 24338691
[TBL] [Abstract][Full Text] [Related]
31. Group A streptococcus epidemiology and vaccine implications.
Cohen-Poradosu R; Kasper DL
Clin Infect Dis; 2007 Oct; 45(7):863-5. PubMed ID: 17806050
[No Abstract] [Full Text] [Related]
32. Induction of a mucosal immune response to the streptococcal M protein by intramuscular administration of a PADRE-ASREAK peptide.
Pamonsinlapatham P; Decroix N; Mihaila-Amrouche L; Bouvet A; Bouvet JP
Scand J Immunol; 2004 May; 59(5):504-10. PubMed ID: 15140061
[TBL] [Abstract][Full Text] [Related]
33. The emm-type diversity does not always reflect the M protein genetic diversity--is there a case for designer vaccine against GAS.
Smeesters PR; Dramaix M; Van Melderen L
Vaccine; 2010 Jan; 28(4):883-5. PubMed ID: 19963033
[No Abstract] [Full Text] [Related]
34. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
Mannam P; Jones KF; Geller BL
Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
[TBL] [Abstract][Full Text] [Related]
35. Enhancing Vaccine Efficacy by Engineering a Complex Synthetic Peptide To Become a Super Immunogen.
Nordström T; Pandey M; Calcutt A; Powell J; Phillips ZN; Yeung G; Giddam AK; Shi Y; Haselhorst T; von Itzstein M; Batzloff MR; Good MF
J Immunol; 2017 Oct; 199(8):2794-2802. PubMed ID: 28904125
[TBL] [Abstract][Full Text] [Related]
36. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.
Wozniak A; Scioscia N; García PC; Dale JB; Paillavil BA; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM
Microbiol Immunol; 2018 Jun; 62(6):395-404. PubMed ID: 29704396
[TBL] [Abstract][Full Text] [Related]
37. Group A streptococcal vaccines: facts versus fantasy.
Steer AC; Batzloff MR; Mulholland K; Carapetis JR
Curr Opin Infect Dis; 2009 Dec; 22(6):544-52. PubMed ID: 19797947
[TBL] [Abstract][Full Text] [Related]
38. The quest for GAS vaccine.
Pandey M; Good MF
Oncotarget; 2015 Oct; 6(33):34063-4. PubMed ID: 26485764
[No Abstract] [Full Text] [Related]
39. Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes.
Penfound TA; Chiang EY; Ahmed EA; Dale JB
Vaccine; 2010 Jul; 28(31):5017-22. PubMed ID: 20546830
[TBL] [Abstract][Full Text] [Related]
40. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY
Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]